pergolide (Permax, pergolidum)

From Aaushi
Jump to navigation Jump to search

Introduction

Withdrawn from US Market 2007

Tradename: Permax.

Indications

Dosage

  • start 0.05 mg PO QD
  • increase by 0.1-0.15 mg every 3rd day over 12 days to 1 mg PO TID
  • max 5 mg/day (no added benefit of higher doses)

Tabs: 0.05, 0.25, 1 mg

Pharmacokinetics

  • 90% of drug is protein-bound
  • at least 10 metabolites are known; it is not known if any of them are active
  • eliminated in the urine

elimination via kidney

Adverse effects

Drug interactions

Mechanism of action

More general terms

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 1051
  3. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  5. Bronstein J, In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 29-Oct 2, 2004
  6. 6.0 6.1 Schade R et al, Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007 Jan 4; 356:29-38
    Zanettini R et al, Valvular heart disease during treatment with dopamine agonists for Parkinson's disease. N Engl J Med 2007 Jan 4; 356:39-46 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17202454
    Roth BL. Drugs and valvular heart disease. N Engl J Med 2007 Jan 4; 356:6-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17202450
    Prescriber's Letter 14(2): 2007 Drug-induced heart valve dysfunction Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230206&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. 7.0 7.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2007/safety07.htm#Pergolide

Database